Ardent Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ardent Health (ARDT).

Price Target Range — 9 Quarters

Analyst Consensus — 13 Analysts

9Buy

3Hold

1Sell

Consensus RatingBuy# Analysts13Avg. Consensus PT$16Upside to Avg. PT+51.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	BMO Capital	Sean Dodge	Initiate	Market Perform	$11
Sep 18, 2026	Leerink Partners	Whit Mayo	Maintained	Outperform	$14
Aug 10, 2026	RBC Capital	Ben Hendrix	PT Raise	Outperform	$12→$13
Aug 6, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$12→$13
Aug 6, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$13→$14
Jul 14, 2026	Truist Securities	David Macdonald	PT Cut	Buy	$13→$12
Jul 9, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$13→$12
May 7, 2026	UBS	A.J. Rice	PT Raise	Buy	$13→$14
Mar 10, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$14→$13
Mar 6, 2026	Leerink Partners	Whit Mayo	PT Cut	Outperform	$16→$15
Jan 20, 2026	JP Morgan	Benjamin Rossi	PT Cut	Neutral	$12→$11
Dec 18, 2025	UBS	A.J. Rice	PT Cut	Buy	$15→$14
Dec 18, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$20→$12
Nov 24, 2025	JP Morgan	Benjamin Rossi	PT Cut	Neutral	$15→$12
Nov 18, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$20→$13
Nov 18, 2025	Guggenheim	Jason Cassorla	PT Cut	Buy	$18→$15
Nov 17, 2025	Keybanc	Matthew Gillmor	Downgrade	Overweight→Sector Weight	—
Nov 14, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$21→$16
Nov 14, 2025	Truist Securities	David Macdonald	PT Cut	Buy	$21→$13
Nov 14, 2025	Stephens & Co.	Scott Fidel	PT Cut	Overweight	$21→$17

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11

BMO Capital analyst Sean Dodge initiates coverage on Ardent Health (NYSE:ARDT) with a Market Perform rating and announces Price Target of $11.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

Guggenheim analyst Jason Cassorla maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and lowers the price target from $13 to $12.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12

RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and lowers the price target from $13 to $12.

Benzinga Newsdesk

Ardent Health Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Ardent Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11

PRO
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

PRO
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

PRO
Guggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

PRO
Truist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

PRO
RBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12

People Also Watch

People Also Watch

Ardent Health Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Ardent Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11

PRORBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

PROTruist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

PROGuggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

PROTruist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

PRORBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12

People Also Watch

People Also Watch

PRO
BMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11

PRO
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

PRO
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

PRO
Guggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

PRO
Truist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

PRO
RBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12